JP2020510050A - がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 - Google Patents

がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 Download PDF

Info

Publication number
JP2020510050A
JP2020510050A JP2019549569A JP2019549569A JP2020510050A JP 2020510050 A JP2020510050 A JP 2020510050A JP 2019549569 A JP2019549569 A JP 2019549569A JP 2019549569 A JP2019549569 A JP 2019549569A JP 2020510050 A JP2020510050 A JP 2020510050A
Authority
JP
Japan
Prior art keywords
tumor
cancer
csf
oncovex
mgm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019549569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510050A5 (https=
Inventor
ベルトラン，ペドロ・ジェイ
ビアーズ，コートニー
クック，キーガン
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2020510050A publication Critical patent/JP2020510050A/ja
Publication of JP2020510050A5 publication Critical patent/JP2020510050A5/ja
Priority to JP2023066170A priority Critical patent/JP7654708B2/ja
Priority to JP2025043270A priority patent/JP2025094078A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019549569A 2017-03-15 2018-03-14 がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 Pending JP2020510050A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023066170A JP7654708B2 (ja) 2017-03-15 2023-04-14 がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用
JP2025043270A JP2025094078A (ja) 2017-03-15 2025-03-18 がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471875P 2017-03-15 2017-03-15
US62/471,875 2017-03-15
PCT/US2018/022442 WO2018170133A1 (en) 2017-03-15 2018-03-14 Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023066170A Division JP7654708B2 (ja) 2017-03-15 2023-04-14 がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用

Publications (2)

Publication Number Publication Date
JP2020510050A true JP2020510050A (ja) 2020-04-02
JP2020510050A5 JP2020510050A5 (https=) 2021-04-22

Family

ID=61913527

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019549569A Pending JP2020510050A (ja) 2017-03-15 2018-03-14 がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用
JP2023066170A Active JP7654708B2 (ja) 2017-03-15 2023-04-14 がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用
JP2025043270A Pending JP2025094078A (ja) 2017-03-15 2025-03-18 がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023066170A Active JP7654708B2 (ja) 2017-03-15 2023-04-14 がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用
JP2025043270A Pending JP2025094078A (ja) 2017-03-15 2025-03-18 がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用

Country Status (9)

Country Link
US (2) US20200009204A1 (https=)
EP (1) EP3595690A1 (https=)
JP (3) JP2020510050A (https=)
CN (1) CN110461346A (https=)
AU (2) AU2018235944B2 (https=)
CA (1) CA3056392A1 (https=)
MA (1) MA51630A (https=)
MX (3) MX2019010797A (https=)
WO (1) WO2018170133A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6457940B2 (ja) * 2012-08-30 2019-01-23 アムジエン・インコーポレーテツド 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
CA3071599A1 (en) * 2017-08-07 2019-02-14 Amgen Inc. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus
CN110833622A (zh) * 2018-08-17 2020-02-25 北京奥源和力生物技术有限公司 用于治疗癌症的组合及其治疗用途
TWI894357B (zh) * 2020-09-18 2025-08-21 大陸商成都美杰賽爾生物科技有限公司 溶瘤病毒與經改造的免疫細胞聯合治療腫瘤
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer
WO2022252185A1 (zh) 2021-06-03 2022-12-08 上海允英生物医药科技有限公司 溶瘤病毒载体及其应用
TW202321458A (zh) * 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
US12129634B2 (en) * 2022-08-23 2024-10-29 Vetta, Llc Sink system
CN115463161A (zh) * 2022-09-15 2022-12-13 广东天普生化医药股份有限公司 一种溶瘤病毒在制备治疗骨肉瘤的药物组合物中的应用
CN116271052B (zh) * 2022-11-11 2025-07-04 上海市普陀区中心医院 溶瘤病毒vg161或与免疫检查点抑制剂联用在治疗胃癌中的应用
WO2024207425A1 (en) * 2023-04-07 2024-10-10 Virogin Biotech (Shanghai) Ltd. Combination of recombinant oncolytic virus and checkpoint inhibitor for the treatment of cancer
CN120648657A (zh) * 2024-03-08 2025-09-16 上海锦斯生物技术有限公司 一种修饰的溶瘤病毒及其组合物
CN119524123A (zh) * 2024-11-08 2025-02-28 北京肿瘤医院(北京大学肿瘤医院) 溶瘤病毒联合pd-1单抗在制备黑色素瘤治疗药物中的应用
CN119792537B (zh) * 2025-01-22 2025-10-21 常州大学 利巴韦林与pd-1抑制剂联合用药物组合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526525A (ja) * 2012-08-30 2015-09-10 アムジエン・インコーポレーテツド 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
WO2016009017A1 (en) * 2014-07-16 2016-01-21 Institut Gustave-Roussy Combination of oncolytic virus with immune checkpoint modulators
WO2017013419A1 (en) * 2015-07-20 2017-01-26 Virttu Biologics Limited Use of oncolytic herpes simplex virus, alone or in combination with immune checkpoint inhibitor, in the treatment of cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP1141338A4 (en) 1998-12-31 2002-09-25 Arch Dev Corp RECOMBINANT HERPES SIMPLEX VIRUS FOR TREATING NEOPLASTIC DISEASES
AU2905199A (en) 1999-03-15 2000-10-04 Trustees Of The University Of Pennsylvania, The Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
DE60115600T2 (de) 2000-01-21 2006-07-20 Biovex Ltd. Virusstämme für die onkolytische behandlung von krebs
CN1286303A (zh) 2000-08-17 2001-03-07 上海市农业科学院生物技术研究中心 抗人龋齿致病菌蛋白基因及其制备方法
CA2441663C (en) 2001-03-27 2013-01-22 Medigene, Inc. Viral vectors and their use in therapeutic methods
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CN101230335B (zh) 2007-01-22 2010-08-11 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
CN101230334B (zh) 2007-01-22 2011-06-01 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
ES2704632T3 (es) 2011-09-08 2019-03-19 Univ New York Virus de herpes simplex oncolítico y sus usos terapéuticos
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
PT3151921T (pt) * 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
WO2017120670A1 (en) * 2016-01-11 2017-07-20 Brian Lichty Oncolytic virus and checkpoint inhibitor combination therapy
PL3426271T3 (pl) * 2016-03-10 2025-11-24 Cg Oncology, Inc. Sposoby leczenia guzów litych terapią skojarzoną
EP3225253A1 (en) * 2016-04-01 2017-10-04 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
JP2020501589A (ja) * 2016-12-23 2020-01-23 ウイルツ・バイオロジクス・リミテッド がんの治療

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526525A (ja) * 2012-08-30 2015-09-10 アムジエン・インコーポレーテツド 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
WO2016009017A1 (en) * 2014-07-16 2016-01-21 Institut Gustave-Roussy Combination of oncolytic virus with immune checkpoint modulators
WO2017013419A1 (en) * 2015-07-20 2017-01-26 Virttu Biologics Limited Use of oncolytic herpes simplex virus, alone or in combination with immune checkpoint inhibitor, in the treatment of cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANN. SURG. ONCOL., 2010, VOL.17, PP.718-730, JPN6022011189, ISSN: 0004947414 *
CANCER RES., 2015, VOL.75, 15_SUPPL., ABSTRACT NO.258, JPN6022011190, ISSN: 0004737239 *
CANCER SCI., 2016, VOL.107, PP.1373-1379, JPN6022011188, ISSN: 0004947415 *
CLINICALTRIALS.GOV., "STUDY OF TALIMOGENE LAHERPAREPVEC IN CHILDREN WITH ADVANCED NON CNS TUMORS", 2, JPN6022011187, ISSN: 0004947416 *
GENE THERAPY, 2003, VOL.10, PP.292-303, JPN6022011185, ISSN: 0004737243 *
MOLECULAR THERAPY, 2013, VOL.21, NO.5, PP.1014-1023, JPN6022011193, ISSN: 0004737238 *

Also Published As

Publication number Publication date
US20260102446A1 (en) 2026-04-16
JP2023089171A (ja) 2023-06-27
CN110461346A (zh) 2019-11-15
MX2019010797A (es) 2019-10-24
AU2024202086A1 (en) 2024-04-18
JP2025094078A (ja) 2025-06-24
AU2018235944B2 (en) 2024-01-04
WO2018170133A1 (en) 2018-09-20
US20200009204A1 (en) 2020-01-09
MX2025001102A (es) 2025-03-07
JP7654708B2 (ja) 2025-04-01
EP3595690A1 (en) 2020-01-22
CA3056392A1 (en) 2018-09-20
MX2024006614A (es) 2024-06-19
AU2018235944A1 (en) 2019-09-26
MA51630A (fr) 2020-01-22

Similar Documents

Publication Publication Date Title
JP7654708B2 (ja) がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用
US20200078426A1 (en) Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
JP6656349B2 (ja) 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
JP6954648B2 (ja) 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
RU2702332C2 (ru) Антитела к в7-н1 и к ctla-4 для лечения немелкоклеточного рака легкого
TWI851676B (zh) 溶瘤病毒用於治療癌症之用途
EP3473263A1 (en) Combined preparations for the treatment of cancer or infection
TWI817958B (zh) 用於治療肝癌之組合物及方法
TW202102543A (zh) 溶瘤病毒在癌症新輔助療法中之用途
US20140205609A1 (en) Methods for inducing systemic immune responses to cancer
CN108815188A (zh) 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途
RU2802962C2 (ru) Композиции и способы лечения рака печени
WO2022048574A1 (zh) 一种编码Kras基因突变体的核酸分子
CN111405906A (zh) 用于治疗癌症的组合物和方法
HK1255016A1 (en) Methods of treating solid or lymphatic tumors by combination therapy
HK1255016B (zh) 通过组合疗法治疗实体或淋巴肿瘤的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221220